Expanded Access to ABBV-8E12

Primary Tauopathy Corticobasal Degeneration Syndrome (CBD) Clinical Trial

Official title:

Expanded Access to ABBV-8E12

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT03744546
• Other study ID #: C19-364
• Secondary ID: C19-921
• Status: No longer available

Study information

• Verified date: August 2019
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-8E12 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Related Conditions & MeSH terms

• Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
• Tauopathies

Intervention

Drug:
• ABBV-8E12
Solution for infusion

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie